{"id":"eucorvac-19","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EuCorVac-19 uses recombinant technology to produce SARS-CoV-2 spike protein (S protein) antigens that are administered to trigger both humoral and cellular immune responses. The vaccine is designed to induce neutralizing antibodies and T-cell immunity against the coronavirus, providing protection against COVID-19 infection and severe disease.","oneSentence":"EuCorVac-19 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:51.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults"}]},"trialDetails":[{"nctId":"NCT05603052","phase":"PHASE3","title":"A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2022-07-11","conditions":"COVID-19","enrollment":2852},{"nctId":"NCT05572879","phase":"PHASE3","title":"A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2022-10-01","conditions":"COVID-19","enrollment":2600},{"nctId":"NCT04783311","phase":"PHASE1, PHASE2","title":"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2021-02-23","conditions":"COVID-19","enrollment":279}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"EuCorVac-19","genericName":"EuCorVac-19","companyName":"EuBiologics Co.,Ltd","companyId":"eubiologics-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"EuCorVac-19 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens. Used for COVID-19 prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}